Clinical Characteristics and Outcomes in NSCLC Patients Associated with Very High PD-L1 Expression

被引：0
|
作者：
Mcloughlin, E. [1 ]
Hanson, L. [2 ]
Moore, M. [3 ]
Horton, B. [4 ]
Gentzler, R. [1 ]
Hall, R. [1 ]
机构：
[1] Univ Virginia, Div Hematol Oncol, Charlottesville, VA USA
[2] Univ Virginia, Med, Charlottesville, AL USA
[3] Univ Virginia, Sch Med, Charlottesville, AL USA
[4] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, AL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Non-Small Cell Lung Cancer; metastatic;
D O I：
10.1016/j.jtho.2019.08.1395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-52
引用
收藏
页码：S659 / S660
页数：2
相关论文
共 50 条
  • [1] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
  • [2] Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
    Zhang, Jie
    Gao, Jing
    Li, Yanyan
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Wu, Di
    Shen, Lin
    Fang, Jian
    THORACIC CANCER, 2015, 6 (04) : 534 - 538
  • [3] Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
    Sanchez-Gastaldo, Amparo
    Munoz-Fuentes, Miguel A.
    Molina-Pinelo, Sonia
    Alonso-Garcia, Miriam
    Boyero, Laura
    Bernabe-Caro, Reyes
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2509 - +
  • [4] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [5] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
    Miyakoshi, Jun
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Ohe, Yuichiro
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Tumor PD-L1 expression is associated with outcomes in stage 3 NSCLC patients treated with consolidation durvalumab
    Jazieh, Khalid
    Gad, Mohamed
    Saad, Anas
    Wei, Wei
    Pennell, Nathan A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3071 - 3078
  • [7] Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients
    He, Jiabei
    Pan, Yuanqing
    Guo, Yang
    Li, Baolan
    Tang, Yu
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (05) : 156 - 164
  • [8] PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
    Wu, Chiao-En
    Chang, Ching-Fu
    Kou-Sheng, Liao
    Chiang, Ju
    Lee, Shih-Wei
    Chiu, Yu-Chi
    ANALYTICAL CELLULAR PATHOLOGY, 2020, 2020
  • [9] PD-L1 expression and its effect on clinical outcomes of EGFRmutant NSCLC patients treated with EGFR-TKIs
    Yuchen Bai
    Xiaoxia Chen
    Likun Hou
    Jun Qian
    Tao Jiang
    Caicun Zhou
    Maciej Ciebiada
    Cancer Biology & Medicine, 2018, 15 (04) : 434 - 442
  • [10] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
    Masuda, Ken
    Horinouchi, Hidehito
    Tanaka, Midori
    Higashiyama, Ryoko
    Shinno, Yuki
    Sato, Jun
    Matsumoto, Yuji
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
12345